Abbott Laboratories (ABT) Stock Buyback History
TTM buyback yield 0.44% · Shareholder yield (TTM) 0.44%.
TTM buyback yield
0.44%
Shareholder yield (TTM)
0.44%
5Y share count change
-2.2%
TTM buyback spend
$793.00M
SBC coverage (TTM)
1.15x
YoY change in spend
-31.0%
5Y CAGR of spend
+17.2%
Peak year (2022)
$3.79B
Cumulative spend
$34.08B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Abbott Laboratories (ABT) repurchased about $793.00M of stock over the trailing twelve months.
- Diluted share count is down 2.2% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 1.15× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +17.2% per year over the latest 5-year window.
- TTM repurchases used about 25% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $893.00M | $664.00M | $229.00M | 1.75B | -0.1% | 0.41% |
| 2024 | $1.29B | $673.00M | $622.00M | 1.75B | -0.1% | 0.66% |
| 2023 | $1.23B | $644.00M | $583.00M | 1.75B | -0.9% | 0.64% |
| 2022 | $3.79B | $685.00M | $3.11B | 1.76B | -1.4% | 1.99% |
| 2021 | $2.30B | $640.00M | $1.66B | 1.79B | 0.2% | 0.93% |
| 2020 | $403.00M | $546.00M | −$143.00M | 1.79B | 0.3% | 0.21% |
| 2019 | $718.00M | $519.00M | $199.00M | 1.78B | 0.6% | 0.47% |
| 2018 | $238.00M | $477.00M | −$239.00M | 1.77B | 1.2% | 0.19% |
| 2017 | $827.00M | $406.00M | $421.00M | 1.75B | 17.9% | 0.83% |
| 2016 | $522.00M | $310.00M | $212.00M | 1.48B | -1.5% | 0.92% |
| 2015 | $2.24B | $292.00M | $1.95B | 1.51B | -1.4% | 3.38% |
| 2014 | $2.19B | $246.00M | $1.95B | 1.53B | -3.0% | 3.23% |
| 2013 | $1.60B | $262.00M | $1.34B | 1.57B | -1.1% | 2.70% |
| 2012 | $2.36B | $433.00M | $1.93B | 1.59B | 1.4% | 4.84% |
| 2011 | $77.01M | $383.00M | −$305.99M | 1.57B | 0.9% | 0.18% |
| 2010 | $866.83M | $387.18M | $479.64M | 1.56B | 0.1% | 2.43% |
| 2009 | $826.35M | $366.36M | $459.99M | 1.55B | -0.4% | 2.07% |
| 2008 | $1.08B | $347.01M | $734.79M | 1.56B | 0.0% | 2.74% |
| 2007 | $1.06B | $46.33M | $1.01B | 1.56B | 1.5% | 2.55% |
| 2006 | $754.50M | $136.47M | $618.03M | 1.54B | -1.8% | 2.10% |
| 2005 | $1.30B | $9.74M | $1.29B | 1.56B | -0.4% | 4.51% |
| 2004 | $499.75M | $10.22M | $489.52M | 1.57B | -0.1% | 1.44% |
| 2003 | $97.62M | $7.66M | $89.96M | 1.57B | -0.1% | 0.30% |
| 2002 | $0.00 | $11.72M | −$11.72M | 1.57B | 0.5% | — |
| 2001 | $17.36M | $0.00 | $17.36M | 1.57B | 0.0% | 0.04% |
| 2000 | $464.86M | $0.00 | $464.86M | 1.57B | 0.5% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 1.56B | -0.2% | — |
| 1998 | $876.30M | $0.00 | $876.30M | 1.56B | -0.9% | — |
| 1997 | $1.05B | $0.00 | $1.05B | 1.58B | -0.4% | — |
| 1996 | $808.80M | $0.00 | $808.80M | 1.58B | — | — |
| 1995 | $771.41M | $0.00 | $771.41M | — | — | — |
| 1994 | $615.95M | $0.00 | $615.95M | — | — | — |
| 1993 | $465.82M | $0.00 | $465.82M | — | — | — |
| 1992 | $607.60M | $0.00 | $607.60M | — | — | — |
| 1991 | $317.80M | $0.00 | $317.80M | — | — | — |
| 1990 | $605.60M | $0.00 | $605.60M | — | — | — |
| 1989 | $289.50M | $0.00 | $289.50M | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Abbott Laboratories (ABT) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Abbott Laboratories (ABT)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Abbott Laboratories (ABT)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $893.00M | -31.0% | -$402.00M | ||
| 2024 | $1.29B | +5.5% | +$68.00M | ||
| 2023 | $1.23B | -67.7% | -$2.57B | ||
| 2022 | $3.79B | +65.1% | +$1.50B | ||
| 2021 | $2.30B | +470.5% | +$1.90B | ||
| 2020 | $403.00M | -43.9% | -$315.00M | ||
| 2019 | $718.00M | +201.7% | +$480.00M | ||
| 2018 | $238.00M | -71.2% | -$589.00M | ||
| 2017 | $827.00M | +58.4% | +$305.00M | ||
| 2016 | $522.00M | -76.7% | -$1.72B | ||
| 2015 | $2.24B | +1.9% | +$42.00M | ||
| 2014 | $2.19B | +36.8% | +$590.00M | ||
| 2013 | $1.60B | -32.1% | -$759.00M | ||
| 2012 | $2.36B | +2969.9% | +$2.29B | ||
| 2011 | $77.01M | -91.1% | -$789.82M | ||
| 2010 | $866.83M | +4.9% | +$40.48M | ||
| 2009 | $826.35M | -23.6% | -$255.46M | ||
| 2008 | $1.08B | +2.2% | +$23.01M | ||
| 2007 | $1.06B | +40.3% | +$304.29M | ||
| 2006 | $754.50M | -42.1% | -$547.81M | ||
| 2005 | $1.30B | +160.6% | +$802.57M | ||
| 2004 | $499.75M | +411.9% | +$402.13M | ||
| 2003 | $97.62M | — | +$97.62M | ||
| 2002 | $0 | -100.0% | -$17.36M | ||
| 2001 | $17.36M | -96.3% | -$447.49M | ||
| 2000 | $464.86M | — | +$464.86M | ||
| 1999 | $0 | -100.0% | -$876.30M | ||
| 1998 | $876.30M | -16.9% | -$178.20M | ||
| 1997 | $1.05B | +30.4% | +$245.70M | ||
| 1996 | $808.80M | +4.8% | +$37.39M | ||
| 1995 | $771.41M | +25.2% | +$155.47M | ||
| 1994 | $615.95M | +32.2% | +$150.12M | ||
| 1993 | $465.82M | -23.3% | -$141.78M | ||
| 1992 | $607.60M | +91.2% | +$289.80M | ||
| 1991 | $317.80M | -47.5% | -$287.80M | ||
| 1990 | $605.60M | +109.2% | +$316.10M | ||
| 1989 | $289.50M | — | — |
Abbott Laboratories (ABT) most recent annual buyback spend stands at $893.00M (2025) – plunged 31.0% year-over-year.
Across 2020–2025 (5 years), Abbott Laboratories buyback spend produced a CAGR of +17.2% – with the latest reading among the more recent periods of the dataset.
Between 2022 and 2025, Abbott Laboratories buyback spend plunged 76.5%, falling from $3.79B to $893.00M.
The dataset's maximum buyback spend sits at $3.79B (2022); the minimum reading of $0 dates to 1999.
Within Healthcare, Abbott Laboratories (ABT) ranks 7th among 8 peers we track. The peer median for buyback spend is $2.75B.
Abbott Laboratories Buyback Spend 2025: $893.00M
Abbott Laboratories buyback spend in 2025 was $893.00M, plunged 31.0% below 2024.
Abbott Laboratories Buyback Spend 2024: $1.29B
Abbott Laboratories buyback spend in 2024 was $1.29B, grew 5.5% from 2023.
Abbott Laboratories Buyback Spend 2023: $1.23B
Abbott Laboratories buyback spend in 2023 was $1.23B, plunged 67.7% below 2022.
Abbott Laboratories Buyback Spend 2022: $3.79B
Abbott Laboratories buyback spend in 2022 was $3.79B, surged 65.1% from 2021. This figure represents the highest annual value in the available history.
Abbott Laboratories Buyback Spend 2021: $2.30B
Abbott Laboratories buyback spend in 2021 was $2.30B.
See more financial history for Abbott Laboratories (ABT).
Sector peers by buyback spend
Companies in the same sector as Abbott Laboratories, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 1.15×.
Capital allocation mix
How Abbott Laboratories splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.19B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Abbott Laboratories's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Abbott Laboratories buy back its own stock?
Yes, Abbott Laboratories (ABT) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Abbott Laboratories spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $793.00M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Abbott Laboratories's buyback yield?
TTM buyback yield is about 0.44% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Abbott Laboratories's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.44% combined (TTM-based where available).
Is Abbott Laboratories diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Abbott Laboratories's share count changed?
Diluted weighted average shares changed by about -2.2% over roughly five fiscal years (annual income statement data).
What is Abbott Laboratories's buyback spend?
Latest reported buyback spend for Abbott Laboratories (ABT) is $793.00M (period ending March 31, 2026).
How has Abbott Laboratories buyback spend changed year-over-year?
Abbott Laboratories (ABT) buyback spend changed -31.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Abbott Laboratories buyback spend?
Abbott Laboratories (ABT) buyback spend compound annual growth rate is +17.2% over the most recent 5 years available.
When did Abbott Laboratories buyback spend hit its highest annual value?
Abbott Laboratories buyback spend reached its highest annual value of $3.79B in 2022.
What was Abbott Laboratories buyback spend in 2024?
Abbott Laboratories (ABT) buyback spend in 2024 was $1.29B.
What was Abbott Laboratories buyback spend in 2025?
Abbott Laboratories (ABT) buyback spend in 2025 was $893.00M.
Explore more
ABT Overview
Company profile, financial tools, and key metrics
ABT Revenue Counter
Earns $1,431 every second. See per minute, hour, and day.
ABT Earnings Counter
Earns $199.01 per second net profit. See per minute, hour, and day.
ABT Economic Scale
Exceeds Paraguay's GDP. Compare with world economies.
ABT What If Invested
What if you had invested $1,000? See historical returns from any date.
ABT How It Makes Money
Discover visual breakdown of $45.13B in revenue — where it comes from and where it goes.
ABT Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ABT Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ABT Daily Price Character
Steady · 48.2% historical win rate (green days). Streaks & record days.
ABT Stock Split History
9 splits on record. Dates, ratios, and cumulative multiple.
ABT Dividend Profile
Yield: 2.76%. Safety: 6/8. See full history.
ABT Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
ABT Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
ABT Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
ABT Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.